Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enzalutamide in Non-metastatic Castration Resistant Prostate Cancer
NCT02588001Completed
- Sponsor
- Translational Research Center for Medical Innovation
- Start
- Oct 2015
- Primary completion
- Mar 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of enzalutamide in prostate cancer (PCa), sponsored by Translational Research Center for Medical Innovation. Primary endpoint: Prostate-Specific Antigen Progression-Free Survival at 6 years. Started Oct 2015; status: completed.
02
Drugs
enzalutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT02588001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02588001.